Sinusitis
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Sinusitis is a moderately active landscape with 86 programs across 39 companies. The most active players are Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., Knopp Biosciences, Lyra Therapeutics. 41 therapies are approved with 16 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
1 program
Knopp Biosciences
1 program
Lyra Therapeutics
1 program
Naryx Pharma
1 program
AstraZeneca
2 programs
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
94%
Small molecule
87 of 93 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 93 classified programs, each share of the total. Modality classified for 100% of 95 pipeline programs.
Analysis
Trial Status
76
clinical trials
Clinical Trials
Trial Activity
76 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)